Citadel Advisors’s Gain Therapeutics GANX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $291K | Buy |
161,816
+142,797
| +751% | +$257K | ﹤0.01% | 4650 |
|
|
2025
Q1 | $36.3K | Buy |
19,019
+7,407
| +64% | +$14.1K | ﹤0.01% | 5456 |
|
|
2024
Q4 | $25.1K | Buy |
+11,612
| New | +$25.1K | ﹤0.01% | 5612 |
|
|
2024
Q2 | – | Sell |
-4,223
| Closed | -$15.9K | – | 6238 |
|
|
2024
Q1 | $15.9K | Sell |
4,223
-61,171
| -94% | -$231K | ﹤0.01% | 5593 |
|
|
2023
Q4 | $214K | Buy |
65,394
+19,518
| +43% | +$63.7K | ﹤0.01% | 4546 |
|
|
2023
Q3 | $148K | Buy |
45,876
+9,629
| +27% | +$31.1K | ﹤0.01% | 4680 |
|
|
2023
Q2 | $162K | Buy |
36,247
+18,800
| +108% | +$84.2K | ﹤0.01% | 4543 |
|
|
2023
Q1 | $84.1K | Buy |
+17,447
| New | +$84.1K | ﹤0.01% | 4981 |
|
|
2022
Q1 | – | Sell |
-13,029
| Closed | -$70K | – | 6629 |
|
|
2021
Q4 | $70K | Buy |
+13,029
| New | +$70K | ﹤0.01% | 6050 |
|